List view / Grid view
27 April 2015 | By Victoria White
AbbVie announced new, preliminary safety and efficacy data from the first cohort of its ongoing, Phase 3b RUBY-I study at ILC 2015...
27 April 2015 | By Victoria White
Primary endpoints were successfully met in a Phase III clinical trial evaluating a 12-week daclatasvir-based regimen for the treatment of patients with HCV...
24 April 2015 | By Victoria White
ELPA has launched ‘C: My Journey’, an online resource where people diagnosed with HCV can go to find out more about the condition and how to get support...
24 April 2015 | By Victoria White
Janssen Sciences Ireland UC announced results for its hepatitis C treatment simeprevir at The International Liver Congress™ 2015...
13 April 2015 | By Victoria White
Ichor Medical Systems has announced that it has entered into a product development collaboration and worldwide license agreement with Janssen...
24 March 2015 | By Victoria White
Janssen Health Policy Centre (Janssen Pharmaceutica NV) today unveiled the EU Disease Lens: a digital dashboard that brings insight into 15 major diseases...
10 February 2015 | By Doctors of the World
Doctors of the World - Médecins du Monde is today filing its opposition to the patent granted for sofosbuvir (Sovaldi) with the European Patent Office...
4 December 2014 | By Bristol-Myers Squibb Foundation
The Bristol-Myers Squibb Foundation announced nine new grants totaling more than $3.5 million to strengthen efforts in China and India in the fight against hepatitis B virus (HBV) and hepatitis C virus (HCV) infection by focusing on the most vulnerable, high-risk patient populations...
24 November 2014 | By Enanta Pharmaceuticals, Inc.
Enanta announces CHMP positive opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir(ABT-450)/ritonavir) + EXVIERA™ (dasabuvir) for the treatment of chronic hepatitis C in Europe...
13 November 2014 | By Gilead Sciences
High cure rates in nearly 800 Hepatitis C Virus (HCV patients with advanced liver disease)...
5 November 2014 | By Public Health England
Around half of the people living with hepatitis C infections don’t know it, according to a new publication out today from Public Health England (PHE), “Shooting Up: Infections among people who inject drugs in the United Kingdom 2013”...
22 October 2014 | By GlobalData
The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company to maintain its dominance in an increasingly competitive market...
10 October 2014 | By Janssen
New data demonstrates efficacy and safety of OLYSIO® (simeprevir) in broader patient populations...
28 August 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has signed a cooperative sales agreement with The Chemo-Sero-Therapeutic Research Institute on August 22 for its recombinant adsorbed hepatitis B vaccine (yeast-derived), Bimmugen®...
27 August 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that the European Commission has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus infection in adults...
